Generics 64

Originals

Biosimilars

Medical devices

Nutraceuticals

Filters

Bortezomib manufacturers

64 products found

Filters

64 products found

bortezomib

Vials, injection 3.5 mg

Dossier type
EU CTD
Dossier status
Ready to file
Country of origin
European Union
GMP approvals
EU GMP
Unavailable markets
Albania , Azerbaijan , Bahrain , Belgium , Bulgaria , China , Colombia , Croatia , Cyprus , Czech Republic , Estonia , Greece , Hungary , Iceland , Iran , Israel , Jordan , Kazakhstan , Kuwait , Latvia , Lithuania , Malaysia , Mexico , Netherlands , North Korea , Norway , Oman , Qatar , Romania , Russia , Serbia , Saudi Arabia , Slovakia , Slovenia , Turkey , Ukraine , Vietnam
Comments
Storage below +30 C
Manufacturer #1586
A pharmaceutical manufacturer based in the EU that has been selling its products in Europe, the Middle East, CIS, LATAM, and Asia for 10+ years. The company's production lines are GMP-compliant. Main dosage forms include solid, liquid, and injection. The company prepares dossier in EU CTD format.

Manufacturer usually replies in 6 days

bortezomib

Solution for injection 3,5mg

Dossier type
EU CTD
Dossier status
Ready to file
Country of origin
European Union
GMP approvals
EU GMP
Unavailable markets
Bahrain , Kuwait , Oman , Qatar , Saudi Arabia , United Arab Emirates , Vietnam
Manufacturer #609

A pharmaceutical manufacturer based in Europe that has been active in 60+ countries selling its products in Europe, North America, LATAM, and MENA for 10+ years. The key production line is Rx. Main dosage forms include injectable and oral liquid. The company's production lines are EU GMP-compliant.

Manufacturer usually replies in 6 days

bortezomib

Solution for injection 2.5 mg/1 ml, 3.5 mg/1.4 ml

Dossier type
EU CTD
Dossier status
Ready to file
Country of origin
European Union
GMP approvals
EU GMP
Manufacturer #12922

Manufacturer usually replies in 7 days

bortezomib

Powder for solution for injection 3.5 mg

Dossier type
EU CTD
Dossier status
Ready to file
Country of origin
European Union
GMP approvals
EU GMP
Comments
RLD-Velcade (Jannsen-Cilag)
Manufacturer #19992
A pharmaceutical manufacturer based in the EU that is active in 20+ countries selling its products for 190+ years. Key production lines are Rx, OTC, medical devices, and nutraceuticals. The company's production lines are GMP-compliant. Main therapy areas include anti-infectives, dermatology, and CNS. The company products are prepared in CTD dossier format.

Manufacturer usually replies in 6 days

bortezomib

Vials 3.5 mg/1.4 ml

Dossier type
EU CTD
Dossier status
Under development
Country of origin
European Union
GMP approvals
EU GMP
Manufacturer #614
A pharmaceutical manufacturer based in Europe selling its products in Europe and worldwide for 10+ years. Main dosage forms include injectable and oral dosage forms. The company's production lines are EU GMP-compliant. The main therapeutic area is oncology.

Manufacturer usually replies in 7 days

bortezomib

Vials, lyophilized injection 3.5 mg

Dossier type
EU CTD
Dossier status
Ready to file
Country of origin
European Union
GMP approvals
EU GMP
Manufacturer #17047
A pharmaceutical manufacturer based in the EU that sells its products in Europe, the Middle East, CIS, LATAM, and Asia. Key production lines are pharmaceuticals, bio and nanopharmaceuticals, medical devices, and nutraceuticals. The main therapeutic area is oncology.

Manufacturer usually replies in 10 days

bortezomib

Vials, injection 3.5 mg

Dossier type
EU CTD
Dossier status
Ready to file
Country of origin
European Union
GMP approvals
EU GMP
Unavailable markets
Lebanon , Russia , Vietnam
Registered in
Czech Republic
Manufacturer #358
A pharmaceutical manufacturer based in the EU that is active in 70+ countries worldwide selling its products in the EU, Australia, Pacific region, and Asia for 30+ years. The company owns several manufacturing plants that comply with EU GMP requirements with production facilities for Rx products, OTC products, nutraceuticals, and medical devices. Its key therapy areas are diabetology, oncology, and neuropsychiatry. The company possesses several R&D centers with hundreds of patents and provides e-CTD format dossiers.

Manufacturer usually replies in 23 days

bortezomib

Powder for solution for injection 3.5 mg

Dossier type
EU CTD
Dossier status
Ready to file
Country of origin
European Union
GMP approvals
EU GMP
Unavailable markets
Vietnam
Manufacturer #437
A pharmaceutical manufacturer based in the EU that is active in 40+ countries selling its products in Europe, North America, LATAM, Africa, Middle East, and Asia for 40+ years. Main therapeutics areas include the nervous system, cardiometabolic, and women’s health. The company's production lines are GMP-compliant. The main dosage forms are solid, semi-solid, liquid, and suspension. The company owns branches in the EU, Africa, and LATAM.

Manufacturer usually replies in 11 days

bortezomib

Vials, injection 3.5mg, 1mg

Dossier type
EU CTD
Dossier status
Ready to file
Country of origin
China
GMP approvals
EU GMP
Unavailable markets
United Kingdom
Manufacturer #9300

Manufacturer usually replies in 3 days

bortezomib

Powder for solution for injection/infusion 3.5 mg

Dossier type
US CTD
Dossier status
Ready to file
Country of origin
Canada
GMP approvals
FDA, Canada
Comments
Reference product : Velcade (Janssen)
Manufacturer #278

The company has become a prominent partner of the pharmacy community in North America, with the fastest rising market share among generic leaders. It can provide best-in-class supply reliability thanks to production capacity. In more than 50 countries, it's available locally or through corporate partnerships. R&D expenditures range from $40 million to $50 million per year. They are dedicated to maintaining a customer satisfaction rate of over 95% by continuously enhancing supply chain efficiency.

Manufacturer usually replies in 7 days

bortezomib

Vials, injection 3.5 mg, 17.5 mg/ml

Dossier type
EU CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
EU GMP
Unavailable markets
Costa Rica
Registered in
France , Germany , Ireland , Italy , Malta , Netherlands , Romania , United Kingdom
Manufacturer #1338

Manufacturer usually replies in 7 days

bortezomib

Vials, injection 3.5mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
Argentina
GMP approvals
EU GMP, ANVISA
Available for
Licensing with supply, Distribution only
Manufacturer #11475
The company is situated in South America and over time has expanded producing oncology drugs for Latin America, Asia Pacific, Europe, and North America, including the United States. The goal of the company is to develop and produce high-quality oncology generics and generics with value-added technology or super generics. Part of the goal is also to produce efficient processes that allow us to have competitive prices.

Manufacturer usually replies in 4 days

bortezomib

Vials, injection 2 mg, 3.5 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
EU GMP
Available for
Licensing with supply, Distribution only
Manufacturer #17708

Manufacturer usually replies in 4 days

bortezomib

Injection, lyophilized 1 mg, 2 mg, 3.5 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
EU GMP
Manufacturer #15176

Manufacturer usually replies in 5 days

bortezomib

Injection 2.5 mg/ml, 3.5 mg/1.4 ml

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
EU GMP
Manufacturer #15176

Manufacturer usually replies in 5 days

bortezomib

Powder and solvent for solution for injection 3.5 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
Turkey
GMP approvals
EU GMP, PICS
Manufacturer #2760

Manufacturer usually replies in 5 days

bortezomib

Vials, injection 2 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
EU GMP, WHO, India
Available for
Licensing with supply, Distribution only
Manufacturer #19588

Manufacturer usually replies in 7 days

bortezomib

Vials, lyophilized injection 3.5 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
Turkey
GMP approvals
EU GMP, ANVISA
Manufacturer #2722
It originally entered the pharmaceutical industry in 1987, when it introduced blood derivative products to Europe and became the exclusive distributor for prominent European brands. Oncology, hematology, dermatology, radiology, rheumatology, immunology, and OTC products are the seven main therapeutic fields.

Manufacturer usually replies in 6 days

bortezomib

Solution for injection 2mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
EU GMP, WHO
Manufacturer #9406

Manufacturer usually replies in 7 days

bortezomib

Powder for solution for infusion 3.5 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
WHO
Manufacturer #12319

Manufacturer usually replies in 5 days

Want to view all 64 products? Create your free account today!

Bortezomib Manufacturers

Bortezomib comes under the class of antineoplastic agents. Bortezomib is prescribed for Multiple Myeloma (MM) and Mantle Cell Lymphoma. Bortezomib comes under the drug category of the first-line approved drug as proteasome inhibitor approved by FDA in the year 2005. It is a highly active agent for the clinical treatment of cancer (MM) and this drug has reversibly inhibiting abilities with proteasomal activities which helps in oncogenic pathways in tumor cells. Manufacturers market Bortezomib with a Brand name of Velcade, Bortrac, Onboard. Bortezomib is advised as a prescription product as well as a generic prescription product. Bortezomib comes in a dosage form of Injection, Lyophilized Powder for reconstitution, and is available in a dosage strength of 3.5 mg /1, 1 mg/1 ml. Bortezomib for Injection is supplied as individually cartooned 10 mL vials containing 3.5 mg of bortezomib which is of single-use. Before using this medication, the risk of taking the drug must be weighed against the benefits it provides. It is always recommended to consult a physician before taking Amphotericin B as this medication may interact with other drugs and health problems. Starting dose of Bortezomib is 1.3 mg/m² which is administered intravenously at a concentration of 1mg/mL twice a week for 2 weeks by a 10-day of resting period and repeated for 6 cycles or by subcutaneously with 2.5mg/ml. Prior to Bortezomib administration, patients need to be premedicated with another drug that is absorbed within the GT like Methylprednisolone. Peak serum concentration is reached at 30 minutes and the drug is cleared within 1 hour. Bortezomib was used progressively in the setting of Solid-organ Transplantation. Optimal effects and responses are obtained with Bortezomib when antibody-mediated rejection is observed in early post-transplant. In recent times there was an observation which was made, and it says that Bortezomib provides effective therapy for antibody mediated rejection in heart and lung transplants. Bortezomib is cytotoxic to a variety of cancer in vitro cell types and causes a delay in tumor growth in vivo cell types, including multiple myeloma. Bortezomib vials may be stored at controlled room temperature 25° C (77° F), with excursions permitted from 15° C to 30° C (59° F to 86° F).

Wholesale price of Bortezomib

The cost for Bortezomib intravenous powder for injection 3.5 mg is around $1,356 for a supply of 1 powder for injection depending on the pharmacy one visits.

Bortezomib - Mechanism of Action

Bortezomib is a selective inhibitor of 26S proteasome, preventing the activation of NF-κB. Though Bortezomib is a reversible inhibitor, it has a low degree of disassociation and remains very stable for several hours. Bortezomib induces apoptosis of rapidly dividing metabolically active cells with extensive protein synthesis. The ability of Bortezomib to target plasma cells as a new therapeutic approach in the treatment or prevention of alloantibody formation in organ transplantation. With the administration of Bortezomib drug progressively distributes into the tissues of the body with an initial plasma distribution- general observation of half-life of bortezomib would be about 10 minutes subsequently with a terminal elimination of more than 40 hours.

Finding Bortezomib Manufacturers and Suppliers

Finding a faithful partner in our business is one of the massive tests and to defeat that challenge and to make one’s work/life easy in finding the credible manufacturer and supplier of Bortezomib one can visit the Pipelinepharma website which helps you in finding the dependable manufacturers and suppliers of Bortezomib. Pipelinepharma, which is a business-to-business (B2B) licensing marketplace for pharmaceutical products, quickly connects the proprietor with the consumers for business development. You can filter the product names in user familiar and unified search engine by their country, category, therapeutic area, forms, dossier, and its status, regulatory filings, approvals, and more.